Introduction
Retrovirus vectors provide a safe and efficient method for gene delivery. Recombinant retrovirus vectors are currently the most widely used vectors in clinical gene therapy trials. 1 They are relatively non-immunogenic, integrate their genome in a stable manner into the genome of infected cells and can be generated with a broad host range. These features are potentially valuable for the permanent correction of monogenic disorders or the delivery of therapeutic genes to treat other diseases. However, current retrovirus vectors are limited by lowvirus titres, which reduce their potential for effective gene delivery. Virus stocks are currently generated from producer cells grown as monolayer cultures. Andreadis et al 1 recently estimated that the volumes of retroviral stocks needed to treat a cancer patient with single or repeat administrations requires the manufacture of between 0.1 and 1.0 l of virus supernatant. This was calculated on the basis of an estimated retroviral titre of 10 6 -10 7 CFU/ml giving a total of between 10 8 and 10 10 CFU. Due to the vast number of individuals requiring potential treatment the volume of virus supernatant needed annually is estimated to be in the region of 10 4 -10 6 l for endstage cancer patients in the USA alone. This is likely to far exceed the capabilities of virus production by current production protocols. An important pre-requisite for suc-titre production. WIL-2 can also be grown as single cells by rotation culture while maintaining virus production. By treating the cells with the transcriptional activator sodium butyrate titres above 1 × 10 6 i.u./ml are achieved. Concentrating viral supernatants by ultrafiltration can further increase virus titre to 5 × 10 8 i.u./ml. Even at these high titres no replication-competent virus was detected. Virus titre fell only slightly when cells were placed in serum-free media before harvest. The generation of this novel cell line provides proof-of-principle that large-scale production of retroviral vectors in serum-free growth conditions can be safely generated for use in gene therapy. Gene Therapy (2001) 8, 697-703.
cessful therapeutic retroviral gene transfer is therefore to increase the quantities of high-titre virus stocks.
Several attempts have been made to increase viral titres. These include improved concentration procedures using ultracentrifugation 2 or ultrafiltration, 3 increasing levels of expression of viral genetic components needed to generate viral particles, [4] [5] [6] and the removal of inhibitors present in viral supernatants which are known to reduce viral infectivity. 7, 8 Conventional retroviral producer cell lines are created by the introduction of the gag/pol and env genes derived from the Moloney murine leukaemia virus (MLV) for packaging the recombinant viral genome carrying a therapeutic or reporter gene. To obtain producers which give high-virus titres individual clones must be isolated and screened from pools of transfected cells.
One major limitation to virus titre is the density at which cells can be grown on culture vessels which has been calculated to be in the region of 2 × 10 6 cells/ml for optimal virus production. 9 The adherent nature of the producer cells currently available for virus production allows virus titres to reach 10 6 -10 7 infectious particles per millilitre. 9, 10 Given the prediction that a standard gene therapy protocol requires in the region of 10 8 -10 10 infectious particles, 1 existing levels of virus production fall considerably short of this need. Monolayer culture also requires large numbers of culture vessels to provide large volumes of virus supernatants thereby making large-scale production of viral supernatants expensive, laborious and time-consuming.
Attempts to use microcarrier systems to enable continuous culture of producer cells and increase virus titre has not been successful in enhancing titres, possibly due to difficulties in providing adequate supplies of vital cellular nutrients to cells tightly packed on beads. 9 In order to overcome the limitations presented by adherent monolayer culture we chose to show proof-ofprinciple that retroviruses can be generated by cells in suspension. Based on the recent discovery that retroviruses generated by adherent cell lines of human origin, as opposed to nonprimate cells, 11, 12 can be resistant to human serum inactivation we have used a human lymphoblastoid cell line WIL-2 with MLV-derived component plasmids. In addition, because most producer cell lines require the presence of serum in their growth medium which is an expensive component that also carries unwanted contaminants such as growth factors, proteins and viruses, we tested the ability of our suspension culture producer cells to generate infectious retroviral particles in the absence of serum. In this report we show that a suspension culture cell line derived from human lymphoblastoid cells can be used to generate high-titre retrovirus vectors under serum-free or low-serum conditions free of contaminating replication-competent viral particles.
Results
WIL-2 cells express infectious ecotropic pseudotyped retrovirus vectors transducing the ␤-galactosidase gene WIL-2 producer cells were tested for their ability to produce retroviral particles by sequential electroporation of the plasmid vectors required to generate infectious retrovirus particles. The plasmid vector pFBMOSALF encoding the ecotropic MLV env gene with a phleomycin selectable marker was introduced into WIL-2 cells and 20 stable WIL-2 env clones were grown for 8 weeks before being examined by Western analysis for env protein expression. Cell lysates from each clone were screened using a goat polyclonal anti-RLV gp69/71 antibody which recognises the MLV gp70 envelope subunit to identify clones with optimal protein expression. Clone WIL-2env4 was identified as the cell line expressing the highest levels of the 70 kDa mature surface subunit (SU) form of the MLV envelope. Comparative ecotropic envelope expression of cell lysates of clone WIL-2env4, negative control WIL-2cells and the positive control cell line TELCeB/MOF-1 are shown in Figure 1 . Clone WIL-2env4 was used for electroporation of the pCeB vector that encodes the MLV gag/pol genes with a blasticidin selectable marker. The transfected pool of WIL2env4gag/pol cells were grown for 10 weeks initially in the presence of blasticidin S. The MFGnlslacZ vector was then introduced into this pool by co-cultivating with TELCeB/AF-7 amphotropic producer cells to achieve 100% infection. PEG precipitated virus produced from the WIL-2env4gag/polMFGnlslacZ cells was tested for env incorporation by Western analysis using the goat polyclonal anti-RLV gp69/71 antibody ( Figure 1) .
From the pool of WIL-2env4gag/polMFGnlslacZ cells 15 stable clones were isolated and the highest gag protein expressing clones were identified by Western analysis using a goat anti-p30 polyclonal antibody. Four of the highest gag producing WIL-2env4gag clones are shown in Figure 2 . Gag protein expression was seen as a 65 kDa precursor and the 30 kDa mature form of the group anti- 
Figure 2 Western analysis of group antigen protein (gag). Western analysis of WIL-2env4gag/pol, MFGnlslacZ-tranduced clones with a goat antip30 antibody showing the presence of the gag precursor protein at 65 kDa and the mature capsid protein p30 (CA) at 30 kDa. Nitrocellulose membrane blotting was performed on a 10% SDS-PAGE gel. Non-electroporated WIL-2 cells were used as a negative control and the TELCeB/MOF1cell line as a positive control.
gen viral capsid. Each of these clones were then screened for reverse transcriptase activity (RT assay) relative to the high-titre producer cell line TELCeB/MOF-1. Quantification of RT activity was determined by densitometry using the NIH Imager analysis program ( Table 1 ). The MFGnlslacZ virus titre obtained from the supernatant of each of the clones shown in Table 1 and Figure 2 with high gag and RT expression and the remaining clones which exhibited low gag or RT expression was determined by infection of NIH3T3 cells (Table 2) . Clone WIL2env4gag9 (designated WIL-E) appeared to produce the highest titre of these clones at 2.5 × 10 4 i.u./ml and 5.5 × 10 4 i.u./ml in the presence of polybrene and DOGS, Reverse transcriptase (RT) activity of four clones out of 15 clones screened following electroporation with the pCeB vector. The RT assay, previously described by Goff et al, 16 was used to determine the relative RT activity of each clone compared with the positive control TELCeB/MOF-1 cell line. No signals were detected for negative control mock-electroporated WIL-2 cells. Activities were quantified by densitometry using the NIH Imager program. Endpoint titration of WIL-2 clones electroporated with gag/pol and ecotropic env plasmids pCeB and pFBMOSALF, respectively, and transduced with the MFGnlslacZ retrovirus generated by the TELCeB/AF-7 amphotropic producer cell line. Infections were carried out in the presence of the polycation DOGS at 5 g/ml.
respectively. Titres of each of the supernatants in the presence of DOGS for each clone are shown in Table 2 . The titres of infectious retroviruses from each clone were analysed repeatedly for a period of 6 months as shown by the infectivity assays using NIH3T3 cells to ensure that a stable suspension culture cell line was established. The absence of replication-competent retrovirus was confirmed using the marker rescue assay. 13 Briefly, NIH 3T3 cells that were infected with the MFGnlslacZ virus produced by WIL-E cells were serially passaged over a period of 2 weeks. Supernatant samples were removed from these cells, filtered and mixed with polybrene or DOGS then placed on to fresh NIH 3T3 cells. These cells were screened by the ␤-galactosidase assay and found to be negative for enzyme activity.
Retrovirus titres are increased with high-density culture of WIL-E cells Recombinant WIL-E producer cells were cultured at three different densities to determine the optimal density for highest virus titre production. All virus supernatants from WIL-E cultures were harvested and titred on Gene Therapy NIH3T3 cells in the presence of the polycation DOGS. Maximum titre was achieved at the cell density of 6 × 10 6 cells/ml. Vector productivity also remained stable at this density for more than 8 weeks. Increasing culturing density further did not result in higher titre. At the density of 6 × 10 6 cells/ml virus titres of 7.5 × 10 5 i.u./ml were reached after an 18 h incubation period (Figure 3 ). Prolonging the incubation period beyond 24 h resulted in a lowering of virus titre. Culturing WIL-E at 6 × 10 6 cells/ml for 18 h was therefore chosen for further experiments to enhance vector titre.
Virus titres improved by the transcription activator sodium butyrate WIL-E cells were grown in the presence of sodium butyrate to increase viral titres; the activation of the MLV LTR promoter to increase virus titre by enhanced transcription of downstream genes has been previously described by Pages et al.
14 A concentration range of between 0 and 20 mm sodium butyrate was used to increase the virus titre to a maximum of 1.3 × 10 6 i.u./ml which was achieved at 10 mm sodium butyrate (Figure 4 ).
WIL-E virus production is maintained under low-serum conditions WIL-E cells were grown in the presence and absence of serum to produce viral particles at high titre in the absence of protein contaminants such as growth factors. Reduced serum would also be beneficial in terms of production costs for large-scale virus preparation in addition to simplifying downstream processing of virus supernatant for concentration and purification. WIL-E cells were grown in suspension medium at a range of serum concentrations between 0 and 15%. Virus titre was evaluated by infection of NIH3T3 cells. In the absence of serum virus titres were reduced from 1.2 × 10 6 i.u./ml to 8.6 × 10 5 i.u./ml, however, titres remained closely compa- rable to those obtained at serum levels between 1% and 15% ( Figure 5 ).
Concentration of viruses by ultrafiltration
WIL-E cells grown in 10 mm sodium butyrate for 18 h in 1% serum containing medium were harvested for concentration by low-speed centrifugal ultrafiltration using Macrosep 300K concentrators (300 kDa exclusion limit) followed by an additional concentration step using Centricon YM-100 columns (100 kDa exclusion limit). This two-step procedure concentrated virus stocks to 5 × 10 8 i.u./ml. (Table 3) . Endpoint titration was performed on NIH3T3 cells. Infection was carried out with filtered supernatants supplemented with DOGS (Transfectam; Promega) at 5 g/ml. Viruses were prepared after incubation of WIL-E cells in 10 mm sodium butyrate for 18 h before harvesting. Virus stocks were concentrated 1000-fold by ultrafiltration resulting in a 500-fold titre enhancement. Virus titre was determined by the mean of three experiments.
Virus production by rotor culturing
We investigated whether WIL-E cells could be adapted to rotor culture to obtain single cell suspensions to optimise virus titre by increasing cell density. WIL-E cells were cultured at 6 × 10 6 cells/ml on a rotoring device (blood cell mixer; Voss, Maldon, UK). WIL-E cells grew as single cell suspensions without a reduction in virus titre. At higher density culture no increase in titre was observed. Although 6 × 10 6 cells/ml appeared to be the maximum cell density possible for optimal virus titre, either as single cells or as clumps of cells growing in culture, cells grown by rotor culturing required little effort to passage.
Serum sensitivity of virus produced by WIL-E
MFGnlslacZ retrovirus particles produced from WIL-E were tested for resistance to complement inactivation as previously described for human cells lines by Cosset et al. 15 Viruses were harvested from WIL-E cells in addition to control particles known to be serum resistant generated from TELCeB/AF-7 15 and Dsh-cxl particles generated by D17 canine producer cells 4 (found to be inactivated by human serum in our laboratory). Viral harvests from each cell line were exposed to human serum at 37°C for 1 h. Infection assays performed on NIH3T3 indicator cells showed that WIL-E virus was highly stable in fresh human serum, retaining above 90% infectivity compared with 43% infectivity of TELCeB/AF-7 infectious particles generated by the human rhabdomyosarcoma TEL671 cell line. 15 The infectivity of Dsh-cxl viruses generated by cells derived from D17 dog cells was reduced to 1% of those not exposed to human serum ( Figure 6 ).
Discussion
We report here the generation of a novel suspension culture producer cell line designated WIL-E capable of generating high-titre retroviruses for use in gene transfer experiments. This cell line produces ecotropic pseudotyped virus stocks for gene transfer research on murine models of genetic diseases. To overcome the limitation set by monolayer cell cultures for high volumes of retrovirus stocks retrovirus producer cells have been previously grown on microcarriers to increase cell densities under continuous bioreactor culture conditions. 9 This,
Figure 6 Serum sensitivity of virus produced by WIL-E. Cell-free virus supernatant from Dsh-cxl, WIL-E and TELCeB/AF-7 packaging cells were mixed 1:1 with human serum and tested for infectivity on indicator cells. Virus titre was expressed as a percentage of the titre after treatment with heat-inactivated serum. Results were collected from three independent experiments.
however, has not produced increased virus titres possibly due to inadequate access of nutrients to cells under the environment of tightly packed cells on beads. Our WIL-E cell line represents the first retrovirus suspension producer cell line which circumvents the restrictive nature of adherent cell culture by being able to grow at high density thereby increasing vector quantity and titre. Given that a standard titre of 10 6 infectious particles per ml is produced by 10 6 producer cells it would require 10 8 producer cells to generate 10 8 particles, the minimum estimated for a typical gene therapy application by Andreadis et al. 1 To apply this to an estimated 10 8 -10 10 particles per patient this would require a large number of culture vessels. In comparison, WIL-E cells which produce 1.3 × 10 6 infectious particles per ml could provide up to 10 10 particles if cultured in a volume under 10 litres which is easily achievable at the bioreactor scale. Naturally the cost of such a protocol would be greatly reduced using WIL-E cells.
To create WIL-E cells the plasmid vectors pFBMOSALF and pCeB (kindly provided by Y Takeuchi) were introduced into the human lymphoblast suspension cell line WIL-2 by sequential electroporation. They have been engineered with reduced homology between the viral sequences and the helper constructs used to package the vector genome. Furthermore, they have been designed for optimised protein expression which has been shown previously to generate high viral titres by human cells. 12, 15 Each vector also provides powerful selection due to the expression of antibiotic resistance genes which helps to maintain stable virus production from transfected WIL-2 cells which was observed for a period in excess of 2 months (data not shown).
Supernatant infection assays showed that WIL-E cells could produce retroviral vectors that transferred the lacZ gene. In accordance with our previous investigations on the influence of cationic compounds on retroviral titre we could increase the infectious titre two-fold by using the polycation DOGS instead of polybrene. The WIL-E packaging cell line did not produce replication-competent virus as shown by the marker rescue assay. 13 A wide variation in virus titres produced from different WIL-2 clones was observed ( Table 2) probably because of the integration of the MFGnlslacZ vector sequences into nonfavourable regions of the WIL-2 genome. Expression of gag, pol and env genes were comparable to that of the TELCeB/MOF-1 high-titre monolayer producer cell line. 12 The difference in titre of the screened WIL-2 clones may also have been due to different numbers of integrated vector genomes between clones although this was not examined. Further screening of WIL-2env4gag/ polMFGnlslacZ clones may produce individual clones producing higher titre virus. Although virus titre in the absence of sodium butyrate induction or concentration is, at 3.5 × 10 5 i.u./ml and 7.5 × 10 5 i.u./ml in the presence of polybrene and DOGS respectively, slightly lower than those achieved with some monlayer producer cell lines, the non-adherant nature of WIL-E cells allows large volumes to be continuously harvested for concentration procedures. The modulation of retroviral expression has been shown previously to increase virus titre by 10-fold in a study by Pages et al, 14 whereas WIL-E cells showed an approximate two-fold increase in titre to 1.3 × 10 6 i.u./ml in the presence of the transcription activator sodium butyrate (Figure 4) . Concentration of virus stocks Gene Therapy allowed titres in excess of 1 × 10 8 iu/ml to be reached (Table 3) .
Ecotropic retroviruses produced by WIL-E cells were remarkably resistant to inactivation by human serum (Figure 6 ). Although the resistance to serum inactivation was tested using ecotropic particles generated by WIL-2 cells the type of receptor used to pseudotype viral particles has not been shown to be the basis for virus inactivation by compliment and therefore the WIL-2 cell line may be valuable for the production of alternative pseudotypes.
The stable generation of retroviral particles by WIL-E cells in the absence of serum during viral harvest is an additional advantage when considering production costs although titres were slightly higher in the presence of a 1% serum level ( Figure 5) . Because of the high percentage survival of WIL-E cells between passages (90-95%) continuous culture and purification of virus particles was made easy. Single cell suspension culture may also be beneficial for the production of VSV-G-pseudotyped particles because VSV-G toxicity is caused by cell-to-cell contact followed by syncitia formation. We hypothesize that VSV-G-pseudotyped C-type retroviral supernatants could be harvested from WIL-2 producer cells and then concentrated to high titre by high-speed centrifugation as shown previously.
2 A VSV-G-pseudotyped WIL-2 producer cell line is currently being investigated using a temperature-sensitive VSV-G envelope.
In conclusion, we have shown proof-of-principle that retroviral vectors can be produced by a suspension culture cell line, WIL-2, in the absence of serum. The establishment of this suspension producer cell line may potentially facilitate large-scale vector production in a bioreactor without the use of trypsin which is required by anchorage-dependent cells. 1 We are currently investigating the culturing of WIL-E cells at the bioreactor scale to prepare large volumes of retroviral stocks to meet potential demands for future applications towards in vivo gene therapy.
Materials and methods

Cell culture and plasmid vectors
The human lymphoblast suspension cell line, WIL-2, was originally isolated from a patient's spleen as cells free from malignancy and believed to be of normal lymphoid origin which grow as single cells or clumps in suspension. 17 WIL-2 cells were kindly gifted by C Arlett (MRC, Sussex, UK). WIL-2 cells were cultured in complete suspension medium (CSM -RPMI 1640 medium supplemented with 15% heat inactivated fetal bovine serum (Australian Origin, Life Technologies, UK) with 2% penicillin/streptomycin, 2% l-glutamine (Life Technologies, UK) and 20% HL-1 medium (Biowhittaker, Wokingham, UK)). NIH3T3 cells were cultured in DMEM supplemented with 10% fetal calf serum and 2% penicillin/streptomycin.
Plasmid DNA extractions were performed using EndoFree Plasmid Maxi Kit (Qiagen, Crawley, UK).
WIL-2 were passaged at a density of 3 × 10 5 cells/ml for optimal cell growth.
The plasmid vectors pCeB encoding MLV gag/pol genes and pFBMOSALF encoding the MLV ecotropic env gene (each provided by Y Takeuchi, University College, Lon-don, UK) were sequentially transfected into WIL-2 cells. 12, 15 Each plasmid vector was electroporated into WIL-2 cells using a Gene Pulser II system (BioRad, Hemel Hempstead, UK). WIL-2 cells were expanded to a density of 1 × 10 7 cells then resuspended in 300 l of 25% preconditioned medium (WIL-2 cell supernatant) then loaded into pre-chilled gene pulser cuvettes (BioRad, UK). Thirty g of each plasmid were used. The cell/plasmid mix was electroporated at 960 F and 250 V. Cells were then incubated at room temperature for 20 min before being transferred to 10 ml of fresh CSM for recovery at 37°C in 5% C0 2 atmosphere. WIL-2 cells were selected in phleomycin and blasticidin at 15 and 20 g/ml for pCeB and pFBMO-SALF vectors, respectively, to obtain stable transfectants.
Western analysis of gag and envelope proteins Expression of gag/pol and env genes was determined by Western analysis according to the method of Laemmli (Molecular Cloning). Primary goat polyclonal anti-RLV gp69/71 antibody which recognises the MLV gp70 envelope subunit was used for env detection and a goat antip30 antibody was used for gag detection (antibodies were supplied by C Porter at the Institute of Cancer Research, London, UK). A secondary antibody, anti-goat HRP-conjugated IgG, (Sigma Immuno Chemicals, Poole, UK) was used. Detection was carried out using an ECL Western analysis kit (Nycomed Amersham, Amersham, UK) to detect the bound protein. Membranes were exposed to autoradiographic film for visualisation.
Reverse transcriptase assay
Reverse transcriptase (RT) assays were performed according to the method of Goff et al. 16 Briefly, 10 l of supernatant samples were taken from cells, and incubated with 50 l of reaction cocktail to give the following final concentration: (50 mm Tris-hydrochloride, pH 8.3: 20 mm dithiothreitol; 0.6 mm MnCl 2 ; 60 mm NaCl; 0.05% Nonidet P-40; 5 g of oligodexoxythymidylic acid per ml; 10 g of polyriboadenylic acid per ml; and 10 m ␣ 32 P dTTP (specific activity, 1 Ci/mmol). The reaction mixture was then incubated at 37°C for 2 h. Ten l of the mixture were then spotted on to DEAE paper (DE-81; Whatman, Maidstone, UK), and dried. The DEAE paper was washed with 2 × SSC solution, then with 95% ethanol. Papers were exposed to X-ray film at −70°C with an intensifying screen. The relative RT activity for each clone was quantified by densitometry using the NIH Imager program (http://rsb.info.nih.gov/nihimage).
Introduction of the MFGnlslacZ vector into Wil-2 cells
The lacZ reporter gene 18 (supplied by Y Takeuchi) was introduced into WIL-2 cells using the TELCeB/AF-7 cell line which produces amphotropic pseudotyped MFGnlslacZ retroviral particles. WIL-2 cells were co-cultured with TELCeB/AF-7 cells based on the method developed by Kozak et al 19 and examined for lacZ gene expression by the ␤-galactosidase reporter assay. 20 WIL-E producer clones were isolated at clonal density by seeding into 96-well culture dishes after dilution to four cell/ml. Cell lines were expanded in culture before titration experiments. Virus containing supernatants were titred after filtration (0.8 m filters; Sartorius, Epsom, UK) in the presence of the polycation polybrene at 4 g/ml or the polyamine DOGS (dioctadecyl dimethyl ammonium chloride -Transfectam; Promega, Southampton, UK) at 5 g/ml as previously described. 21 Vector production under reduced serum conditions Virus producing WIL-E cells were grown at 6 × 10 6 cells/ml in RPMI 1640 medium or complete suspension medium (CSM -RPMI 1640 medium supplemented with 15% serum and 20% HL-1 medium) then transferred to medium with or without serum ( Figure 5 ). Supernatants were harvested after 18 h then titred on NIH3T3 cells.
Enhancement of virus titre by ultrafiltration and LTR activation using sodium butyrate WIL-E cells were cultured at 6 × 10 6 cells/ml in a range of sodium butyrate concentrations (Figures 4) for 18 h before titration. Supernatants were loaded into eight Macrosep 300k membrane tubes (300 kDa molecular weight exclusion; Filtron, Staffordshire, UK) for an initial volume reduction (centrifugation at 2000 g) then transferred into Centricon YM-100 membrane tubes (100 kDa molecular weight exclusion; Amicon, Bedford, MA, USA) followed by centrifugation to reach a final 1000-fold volume reduction. Concentrated supernatant samples were titred on NIH3T3 cells.
Helper virus rescue assay
The presence of replication-competent retrovirus (RCR) was examined by the marker rescue assay as described by Miller and Rosman. 13 Serum sensitivity assay Serum sensitivity assays were carried as described by Cosset et al. 15 
